Skip to main content

Market Overview

UPDATE: Goldman Sachs Upgrades Quest Diagnostics to Buy on Improved Fundamentals

Share:

In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Quest Diagnostics (NYSE: DGX) from Neutral to Buy, and raised the price target from $56.00 to $67.00.

In the report, Ro noted, “We upgrade shares of DGX to Buy from Neutral and raise our 6-month price target to $67 (from $56), which implies 17% upside. After underperforming the S&P, HC peers, and direct comp LH over the past 12 months, we believe DGX is now poised for a turnaround and we see multiple catalysts to drive share outperformance.”

Quest Diagnostics closed on Wednesday at $57.30.

Latest Ratings for DGX

DateFirmActionFromTo
May 2021UBSUpgradesNeutralBuy
Mar 2021Morgan StanleyMaintainsEqual-Weight
Mar 2021BairdDowngradesOutperformNeutral

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

 

Related Articles (DGX)

View Comments and Join the Discussion!

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

Latest Ratings

StockFirmActionPT
SWCHCredit SuisseMaintains20.0
VLDRNeedhamMaintains15.0
SIVBPiper SandlerMaintains650.0
STEJMP SecuritiesMaintains235.0
ZBHJMP SecuritiesMaintains195.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com